{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T05:26:50Z","timestamp":1733808410320,"version":"3.30.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clineuro.2024.108649","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T02:26:13Z","timestamp":1732155973000},"page":"108649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population"],"prefix":"10.1016","volume":"248","author":[{"given":"Hussain M.","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal M.","family":"Alanazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmajeed S.","family":"Namshah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal T.","family":"Alshuaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Albulaihe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem M.","family":"Alhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed H.","family":"Alanazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clineuro.2024.108649_bib1","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s00415-023-11733-y","article-title":"Myasthenia gravis, respiratory function, and respiratory tract disease","volume":"270","author":"Gilhus","year":"2023","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2024.108649_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002024","article-title":"Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study","volume":"13","author":"Fardet","year":"2016","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108649_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/ard.2010.144741","article-title":"The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case\u2013control study","volume":"70","author":"Dixon","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108649_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/mus.26032","article-title":"Infections and the relationship to treatment in neuromuscular autoimmunity","volume":"57","author":"Prior","year":"2018","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.clineuro.2024.108649_bib5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","article-title":"Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia","volume":"32","author":"Caballero-\u00c1vila","year":"2022","journal-title":"Neuromuscul. Disord. NMD"},{"issue":"11","key":"10.1016\/j.clineuro.2024.108649_bib6","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/ene.14391","article-title":"Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study","volume":"27","author":"Dos Santos","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108649_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.clineuro.2024.108649_bib8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.clineuro.2024.108649_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2024.108649_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108649_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clineuro.2024.108649_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pop.2013.06.004","article-title":"Upper respiratory infections","volume":"40","author":"Grief","year":"2013","journal-title":"Prim. Care"},{"issue":"2","key":"10.1016\/j.clineuro.2024.108649_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.27324","article-title":"COVID-19 in patients with myasthenia gravis: epidemiology and disease course","volume":"64","author":"Businaro","year":"2021","journal-title":"Muscle Nerve"},{"issue":"15_ement","key":"10.1016\/j.clineuro.2024.108649_bib14","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1212\/WNL.96.15_supplement.4170","article-title":"Incidence and impact of COVID-19 in a cohort of patients with myasthenia gravis from Barcelona. (4170)","volume":"96","author":"Martinez-Hernandez","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108649_bib15","article-title":"COVID-19 outcomes in myasthenia gravis patients: analysis from electronic health records in the United States","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol."},{"issue":"15_ement","key":"10.1016\/j.clineuro.2024.108649_bib16","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1212\/WNL.96.15_supplement.4382","article-title":"Myasthenia gravis after sARS-CoV-2 infection: a Cerner real-world COVID-19 de-identified dataset analysis (4382)","volume":"96","author":"Patlolla","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.clineuro.2024.108649_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9834","article-title":"Outcomes of COVID-19 infection and vaccination among individuals with myasthenia gravis","volume":"6","author":"Alcantara","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.clineuro.2024.108649_bib18","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clineuro.2024.108649_bib19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2024.108649_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724005365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724005365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T03:57:08Z","timestamp":1733803028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724005365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"alternative-id":["S0303846724005365"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108649","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency of upper respiratory tract infections in patients with myasthenia gravis compared to the general population","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108649"}}